Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Vericel Corporation
ATQPVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Address: 64 Sidney Street, Cambridge, MA, United States, 02139
Analytics
Objectif de Cours de WallStreet
60.03 EURRatio C/B
4040.0002Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés ATQP
Analyse des dividendes ATQP
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes ATQP
Valorisation des titres ATQP
financières ATQP
Résultats | 2019 | Dynamique |